

BIOSIMILARS IPR DASHBOARD

(Current as of 11/14/18)

HUMIRA® (Adalimumab)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2018- 00156	<u>Patent No. 9,187,559</u>	Sandoz	AbbVie	Petition: 11/6/17 POPR: 3/7/18 Inst. Dec.: 6/5/18	<u>Terminated – Institution Denied</u>
IPR 2018- 00002	<u>Patent No. 9,512,216</u>	Sandoz	AbbVie	Petition: 10/2/17 POPR: 2/5/18 Reply to POPR: 3/12/18 Inst. Dec.: 5/3/18 Notice of Appeal: 7/5/18	<u>Terminated – Institution Denied (Notice of Appeal filed)</u>
IPR 2017- 02105	<u>Patent No. 9,090,689</u>	Sandoz	AbbVie	Petition: 9/14/17 Institution: 4/3/18 Term. Dec.: 11/2/18	<u>Terminated – Settlement</u>
IPR 2017- 02106	<u>Patent No. 9,067,992</u>	Sandoz	AbbVie	Petition: 9/14/17 Institution: 4/3/18 Term. Dec.: 11/2/18	<u>Terminated – Settlement</u>
IPR 2017- 01987	<u>Patent No. 8,911,737</u>	Sandoz	AbbVie	Petition: 8/21/17 POPR: 12/13/17 Inst. Dec.: 3/9/18 Req. for Reh'g: 4/6/18 Term. Dec.: 11/2/18	<u>Terminated – Institution Denied; Settlement after Rehearing Request</u>
IPR 2017- 01988	<u>Patent No. 8,974,790</u>	Sandoz	AbbVie	Petition: 8/21/17 POPR: 12/13/17 Inst. Dec.: 3/9/18 Req. for Reh'g: 4/6/18 Term. Dec.: 11/2/18	<u>Terminated – Institution Denied; Settlement after Rehearing Request</u>
IPR 2017- 01823	<u>Patent No. 8,802,100</u>	Sandoz	AbbVie	Petition: 7/20/17 POPR: 11/13/17 Reply to POPR: 12/15/17 Inst. Dec.: 2/9/18	<u>Terminated – Institution Denied</u>
IPR 2017- 01824	<u>Patent No. 9,512,216</u>	Sandoz	AbbVie	Petition: 7/20/17 POPR: 11/13/17 Inst. Dec.: 2/9/18 Reh'g Dec.: 5/3/18 Notice of Appeal: 7/5/18	<u>Terminated – Institution Denied (Rehearing Denied) (Notice of Appeal filed)</u>

IPR 2017- 01008	Patent No. 9,085,619	Coherus	AbbVie	Petition: 3/2/17 POPR: 6/11/17 Inst. Dec.: 9/7/17	Terminated – Institution Denied
IPR 2017- 01009	Patent No. 9,085,619	Coherus	AbbVie	Petition: 3/2/17 POPR: 6/11/17 Inst. Dec.: 9/7/17	Terminated – Institution Denied
IPR 2017- 00822	Patent No. 9,085,619	Coherus	AbbVie	Petition: 1/31/17 POPR: 6/11/17 Inst. Dec.: 9/7/17	Terminated – Institution Denied
IPR 2017- 00823	Patent No. 9,085,619	Coherus	AbbVie	Petition: 1/31/17 POPR: 6/11/17 Inst. Dec.: 9/7/17	Terminated – Institution Denied
IPR 2016- 00408	Patent No. 8,889,135	Boehringer Ingelheim	AbbVie	Petition: 12/29/15 Institution: 7/7/16 Hearing: 4/4/17 Decision: 7/6/17 Notice of Appeal: 7/31/17	Final Written Decision (Notice of Appeal filed)
IPR 2016- 00409	Patent No. 8,889,135	Boehringer Ingelheim	AbbVie	Petition: 12/29/15 Institution: 7/7/16 Hearing: 4/4/17 Decision: 7/6/17 Notice of Appeal: 7/31/17	Final Written Decision (Notice of Appeal filed)
IPR 2016- 00172	Patent No. 8,889,135	Coherus	AbbVie	Petition: 11/9/15 Institution: 5/17/16 Hearing: 2/16/17 Decision: 5/16/17 Notice of Appeal: 7/14/17	Final Written Decision (Notice of Appeal filed)
IPR 2016- 00188	Patent No. 9,017,680	Coherus	AbbVie	Petition: 12/7/15 Institution: 6/13/16 Hearing: 2/16/17 Decision: 6/9/17 Notice of Appeal: 7/14/17	Final Written Decision (Notice of Appeal filed)
IPR 2016- 00189	Patent No. 9,073,987	Coherus	AbbVie	Petition: 12/7/15 Institution: 6/13/16 Hearing: 2/16/17 Decision: 6/9/17 Notice of Appeal: 7/14/17	Final Written Decision (Notice of Appeal filed)
IPR 2016- 01018	Patent No. 9,114,166	Coherus	AbbVie	Petition: 5/9/16 POPR: 8/9/16 Inst. Dec.: 11/7/16 Reh'g Dec.: 2/2/17	Terminated – Institution Denied (Rehearing Denied)

IPR 2015- 01514	Patent No. 8,916,157	Amgen	AbbVie	Petition: 6/26/15 POPR: 10/19/15 Inst. Dec.: 1/14/16	Terminated – Institution Denied
IPR 2015- 01517	Patent No. 8,916,158	Amgen	AbbVie	Petition: 6/26/15 POPR: 10/19/15 Inst. Dec.: 1/14/16	Terminated – Institution Denied

Herceptin® (Trastuzumab)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2018- 00330	Patent No. 6,339,142	Pfizer	Genentech	Petition: 12/18/17 POPR: 4/18/18 Inst. Dec.: 7/9/18	Terminated – Institution Denied
IPR 2018- 00331	Patent No. 9,249,218	Pfizer	Genentech	Petition: 12/18/17 POPR: 4/18/18 Inst. Dec.: 7/9/18	Terminated – Institution Denied
IPR 2018- 00192	Patent No. 7,846,441	Samsung Bioepis	Genentech	Petition: 11/30/17 POPR: 3/19/18 Inst. Dec.: 6/18/18	Terminated – Institution Denied
IPR 2018- 00016	Patent No. 7,846,441	Pfizer	Genentech	Petition: 10/3/17 POPR: 2/2/18 Inst. Dec.: 2/21/18	Terminated – Institution Denied
IPR 2017- 02139	Patent No. 6,407,213*	Samsung Bioepis	Genentech	Petition: 9/29/17 Institution: 2/22/18	Trial Instituted – Joined with IPR2017-01488
IPR 2017- 02140	Patent No. 6,407,213*	Samsung Bioepis	Genentech	Petition: 9/29/17 Institution: 2/22/18	Trial Instituted – Joined with IPR2017-01489
IPR 2017- 02063	Patent No. 7,846,441	Pfizer	Genentech	Petition: 9/6/17 Institution: 2/21/18 Decision: 10/3/18	Final Written Decision (Joined with IPR 2017- 01121)
IPR 2017- 02031	Patent No. 6,407,213*	Boehringer Ingelheim	Genentech	Petition: 8/31/17 Institution: 3/29/18 Term. Dec.: 7/31/18	Terminated – Request for Adverse Jmt. Against Pet.

IPR 2017- 02032	Patent No. 6,407,213*	Boehringer Ingelheim	Genentech	Petition: 8/31/17 Institution: 3/29/18 Term. Dec.: 7/31/18	Terminated – Request for Adverse Jmt. Against Pet
IPR 2017- 02019	Patent No. 6,339,142	Pfizer	Genentech	Petition: 8/29/17 Institution: 3/12/18 Hearing: 1/10/19 Decision: 3/12/19 (est.)	Trial Instituted
IPR 2017- 02020	Patent No. 9,249,218	Pfizer	Genentech	Petition: 8/29/17 Institution: 3/12/18 Hearing: 1/10/19 Decision: 3/12/19 (est.)	Trial Instituted
IPR 2017- 01958	Patent No. 6,627,196	Samsung Bioepis	Genentech	Petition: 8/25/17 Institution: 12/1/17 Decision: 10/3/18	Final Written Decision (Joined with IPR2017- 00804)
IPR 2017- 01959	Patent No. 7,371,379	Samsung Bioepis	Genentech	Petition: 8/25/17 Institution: 12/1/17 Decision: 10/3/18	Final Written Decision (Joined with IPR2017- 00805)
IPR 2017- 01960	Patent No. 7,892,549	Samsung Bioepis	Genentech	Petition: 8/25/17 Institution: 12/1/17 Decision: 10/3/18	Final Written Decision (Joined with IPR2017- 00737)
IPR 2017- 01726	Patent No. 8,591,897	Pfizer	Genentech	Petition: 6/30/17 POPR: 11/3/17 Inst. Dec.: 1/23/18	Terminated – Institution Denied
IPR 2017- 01727	Patent No. 8,591,897	Pfizer	Genentech	Petition: 6/30/17 POPR: 11/3/17 Inst. Dec.: 1/23/18	Terminated – Institution Denied
IPR 2017- 01488	Patent No. 6,407,213*	Pfizer	Genentech	Petition: 5/25/17 Instit.: 12/1/17 (sealed) Hearing: 7/16/18 Decision: 11/30/18 (est.)	Trial Instituted
IPR 2017- 01489	Patent No. 6,407,213*	Pfizer	Genentech	Petition: 5/25/17 Instit.: 12/1/17 (sealed) Hearing: 7/16/18 Decision: 11/30/18 (est.)	Trial Instituted
IPR 2017- 01373	Patent No. 6,407,213*	Celltrion	Genentech	Petition: 5/8/17 Institution: 12/1/17 Hearing: 7/16/18 Decision: 11/30/18 (est.)	Trial Instituted

IPR 2017- 01374	Patent No. 6,407,213*	Celltrion	Genentech	Petition: 5/8/17 Institution: 12/1/17 Hearing: 7/16/18 Decision: 11/30/18 (est.)	Trial Instituted
IPR 2017- 01139	Patent No. 6,627,196	Celltrion	Genentech	Petition: 3/24/17 Institution: 10/4/17 Hearing: 5/8/18 Decision: 10/3/18	Final Written Decision
IPR 2017- 01140	Patent No. 7,371,379	Celltrion	Genentech	Petition: 3/24/17 Institution: 10/4/17 Hearing: 5/8/18 Decision: 10/3/18	Final Written Decision
IPR 2017- 01121	Patent No. 7,846,441	Celltrion	Genentech	Petition: 3/21/17 Institution: 10/4/17 Hearing: 5/18/18 Decision: 10/3/18	Final Written Decision
IPR 2017- 01122	Patent No. 7,892,549	Celltrion	Genentech	Petition 3/21/17 Institution: 10/4/17 Hearing: 5/18/18 Decision: 10/3/18	Final Written Decision
IPR 2017- 00959	Patent No. 8,591,897	Celltrion	Genentech	Petition: 2/21/17 Term. Dec.: 9/11/17	Terminated – Adverse Judgment After Req. for Cancellation
IPR 2017- 00804	Patent No. 6,627,196	Hospira	Genentech	Petition: 1/30/17 Institution: 7/27/17 Hearing: 5/8/18 Decision: 10/3/18 Notice of Appeal: 11/7/18	Final Written Decision (Notice of Appeal filed)
IPR 2017- 00805	Patent No. 7,371,379	Hospira	Genentech	Petition: 1/30/17 Institution: 7/27/17 Hearing: 5/8/18 Decision: 10/3/18 Notice of Appeal: 11/7/18	Final Written Decision (Notice of Appeal filed)
IPR 2017- 00731	Patent No. 7,846,441	Hospira	Genentech	Petition: 1/20/17 Reh'g & Instit.: 10/26/17 Hearing: 5/18/18 Decision: 10/3/18	Final Written Decision
IPR 2017- 00737	Patent No. 7,892,549	Hospira	Genentech	Petition: 1/20/17 Institution: 7/27/17 Hearing: 5/18/18 Decision: 10/3/18	Final Written Decision

IPR 2017- 00739	Patent No. 7,892,549	Hospira	Genentech	Petition: 1/20/17 POPR: 5/3/17 Inst. Dec.: 7/27/17	Terminated – Institution Denied
IPR 2016- 01837	Patent No. 7,807,799	Hospira	Genentech	Petition: 9/16/16 Institution: 3/15/17 Hearing: 11/29/17 Decision: 3/6/18 Notice of Appeal: 5/7/18	Final Written Decision (Notice of Appeal filed)
IPR 2016- 01693	Patent No. 6,407,213*	Mylan	Genentech	Petition: 8/30/16 POPR: 12/16/16 Term. Dec.: 3/10/17	Terminated – Settlement
IPR 2016- 01694	Patent No. 6,407,213*	Mylan	Genentech	Petition: 8/30/16 POPR: 12/16/16 Term. Dec.: 3/10/17	Terminated – Settlement

* The '213 patent is directed to a method of making humanized antibodies. Although the patent does not pertain to a particular biologic, Genentech has stated that the method was used for Herceptin® as well as several other products. We have not repeated the listing for this proceeding elsewhere.

AVASTIN® (Bevacizumab)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2018- 00373	Patent No. 9,795,672	Pfizer	Genentech	Petition: 1/5/18 POPR: 5/8/18 Inst. Dec.: 8/2/18	Terminated – Institution Denied
IPR 2017- 02029	Patent No. 6,870,034	Boehringer Ingelheim	Genentech	Petition: 8/31/17 Institution: 2/15/18 Term. Dec.: 11/7/18	Terminated – Settlement
IPR 2016- 01771	Patent No. 7,622,115	Hospira	Genentech	Petition: 9/9/16 Institution: 3/16/17 Hearing: 1/18/18 Decision: 3/9/18 Notice of Appeal: 5/10/18	Final Written Decision (Notice of Appeal filed)

RITUXAN® (Rituximab)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2018-01019	Patent No. 7,976,838	Celltrion	Genentech	Petition: 5/4/18 Institution: 10/30/18	Trial Instituted – Joined with IPR2017-01923
IPR 2018-00285	Patent No. 8,329,172	Pfizer	Biogen	Petition: 12/14/17 Institution: 7/9/18 Hearing: 3/28/19 Decision: 7/9/19 (est.)	Trial Instituted
IPR 2018-00231	Patent No. 9,504,744	Pfizer	Biogen	Petition: 12/1/17 Terminated: 6/6/18	Terminated – Dismissed with prejudice
IPR 2018-00186	Patent No. 9,296,821	Pfizer	Biogen	Petition: 12/1/17 Institution: 6/14/18 Term. Dec.: 11/8/18	Terminated – Jointly Requested
IPR 2018-00086	Patent No. 8,545,843	Pfizer	Biogen	Petition: 11/2/17 POPR: 3/7/18 Inst. Dec.: 5/31/18	Terminated – Institution Denied
IPR 2017-02126	Patent No. 7,682,612	Pfizer	Biogen and Genentech	Petition: 10/6/17 POPR: 2/6/18 Inst. Dec.: 4/30/18	Terminated – Institution Denied
IPR 2017-02127	Patent No. 8,206,711	Pfizer	Biogen and Genentech	Petition: 10/6/17 POPR: 2/6/18 Inst. Dec.: 4/19/18	Terminated – Institution Denied
IPR 2017-01923	Patent No. 7,976,838	Pfizer	Genentech	Petition: 8/29/17 Institution: 4/4/18 Hearing: 1/17/19 Decision: 4/4/19 (est.)	Trial Instituted
IPR 2017-02036	Patent No. 7,976,838	Sandoz	Genentech	Petition: 8/31/17 POPR: 1/5/18 Reply: 2/2/18 Inst. Dec.: 4/4/18	Terminated – Institution Denied
IPR 2017-02042	Patent No. 7,976,838	Sandoz	Genentech	Petition: 8/31/17 POPR: 1/5/18 Reply: 2/2/18 Inst. Dec.: 4/4/18	Terminated – Institution Denied

IPR 2017- 01166	Patent No. 8,329,172	Pfizer	Biogen	Petition: 4/21/17 POPR: 8/15/17 Inst. Dec.: 11/13/17 Req. for Reh'g: 12/12/17	Terminated – Institution Denied (Rehearing Requested)
IPR 2017- 01167	Patent No. 8,557,244	Pfizer	Biogen	Petition: 4/27/17 POPR: 8/8/17 Inst. Dec.: 11/6/17 Reh'g Dec.: 3/22/18	Terminated – Institution Denied (Rehearing Denied)
IPR 2017- 01168	Patent No. 8,821,873	Pfizer	Biogen	Petition: 4/28/17 Institution: 11/6/17 Hearing: 7/24/18 Decision: 10/31/18	Final Written Decision
IPR 2017- 01227	Patent No. 7,682,612	Celltrion	Biogen and Genentech	Petition: 3/31/17 POPR: 7/24/17 Inst. Dec.: 10/23/17	Terminated – Institution Denied
IPR 2017- 01229	Patent No. 8,206,711	Celltrion	Biogen and Genentech	Petition: 3/31/17 POPR: 7/24/17 Inst. Dec.: 10/23/17	Terminated – Institution Denied
IPR 2017- 01230	Patent No. 7,682,612	Celltrion	Biogen and Genentech	Petition: 3/31/17 POPR: 7/18/17 Inst. Dec.: 10/12/17	Terminated – Institution Denied
IPR 2017- 01115	Patent No. 7,820,161	Pfizer	Biogen	Petition: 3/24/17 Institution: 7/18/17 Decision: 2/21/18	Final Written Decision (Joined with IPR2016- 01614)
IPR 2017- 01093	Patent No. 8,329,172	Celltrion	Biogen	Petition: 3/15/17 POPR: 7/10/17 Inst. Dec.: 10/6/17	Terminated – Institution Denied
IPR 2017- 01094	Patent No. 8,557,244	Celltrion	Biogen	Petition: 3/15/17 POPR: 7/5/17 Inst. Dec.: 10/2/17 Reh'g Dec.: 1/2/18	Terminated – Institution Denied (Rehearing Denied)
IPR 2017- 01095	Patent No. 9,296,821	Celltrion	Biogen	Petition: 3/15/17 Institution: 10/6/17 Hearing: 8/21/18 Decision: 10/4/18	Final Written Decision
IPR 2016- 01667	Patent No. 7,976,838	Celltrion	Genentech	Petition: 8/24/16 POPR: 12/6/16 Inst. Dec.: 3/2/17 Reh'g Dec.: 8/18/17	Terminated – Institution Denied (Rehearing Denied)



IPR 2016- 01614	Patent No. 7,820,161	Celltrion	Genentech and Biogen	Petition: 8/15/16 Institution: 2/24/17 Hearing: 10/31/17 Decision: 2/21/18 Notice of Appeal: 4/25/18	Final Written Decision (Notice of Appeal filed)
IPR 2015- 01733	Patent No. 7,976,838	Celltrion	Genentech	Petition: 8/14/15 Terminated: 10/6/15	Terminated – Dismissed without prejudice
IPR 2015- 01744	Patent No. 7,820,161	Celltrion	Genentech and Biogen	Petition: 8/17/15 Terminated: 10/6/15	Terminated – Dismissed without prejudice
IPR 2015- 00415	Patent No. 7,820,161	Boehringer Ingelheim	Genentech and Biogen	Petition: 12/15/14 POPR: 4/27/15 Institution: 7/17/15 Terminated: 10/1/15	Terminated – Request for Adverse Jmt. Against Pet.
IPR 2015- 00417	Patent No. 7,976,838	Boehringer Ingelheim	Genentech	Petition: 12/15/14 POPR: 4/15/15 Institution: 7/14/15 Terminated: 10/1/15	Terminated – Request for Adverse Jmt. Against Pet.
IPR 2015- 00418	Patent No. 8,329,172	Boehringer Ingelheim	Biogen	Petition: 12/15/14 POPR: 4/15/15 Inst. Dec.: 7/13/15	Terminated – Institution Denied

Neulasta® (Pegfilgrastim)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2016- 01542	Patent No. 8,952,138	Apotex	Amgen	Petition: 8/5/16 Institution: 2/17/17 Hearing: 12/13/17 Decision: 2/15/18 Req. for Reh'g: 3/16/18	Final Written Decision (Rehearing Requested)

Lantus®¹ (Insulin Glargine)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2019-00122	Patent No. 8,992,486	Mylan	Sanofi-Aventis	Petition: 10/29/18 POPR: 1/29/19 (est.) Inst. Dec.: 4/29/19 (est.)	Petition Filed
IPR 2018-01696	Patent No. 9,526,844	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01684	Patent No. 9,604,008	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01682	Patent No. 9,526,844	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01680	Patent No. 9,526,844	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01679	Patent No. 8,992,486	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01678	Patent No. 8,992,486	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01677	Patent No. 8,992,486	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01676	Patent No. 8,603,044	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2018-01675	Patent No. 8,603,044	Mylan	Sanofi-Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed

¹ We note that Sanofi-Aventis's Lantus® (insulin glargine) was approved by the FDA through the 505(b) regulatory pathway as an NDA, not a BLA.

IPR 2018- 01670	Patent No. 8,679,069	Mylan	Sanofi- Aventis	Petition: 9/10/18 POPR: 12/10/18 (est.) Inst. Dec.: 3/8/19 (est.)	Petition Filed
IPR 2017- 01526	Patent No. 7,476,652	Mylan	Sanofi- Aventis	Petition: 6/5/17 Institution: 12/13/17 Hearing: 9/6/18 Decision: 12/13/18 (est.)	Trial Instituted
IPR 2017- 01528	Patent No. 7,713,930	Mylan	Sanofi- Aventis	Petition: 6/5/17 Institution: 12/13/17 Hearing: 9/6/18 Decision: 12/13/18 (est.)	Trial Instituted

Tysabri® (Natalizumab)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2016- 00912	Patent No. 8,815,236	Swiss Pharma Int'l AG	Biogen	Petition: 4/18/16 POPR: 7/20/16 Inst. Dec.: 10/17/16 Reh'g Dec.: 2/3/17	Terminated – Institution Denied (Rehearing Denied)
IPR 2016- 00915	Patent No. 8,349,321	Swiss Pharma Int'l AG	Biogen	Petition: 4/18/16 POPR: 7/20/16 Inst. Dec.: 10/17/16 Reh'g Dec.: 2/3/17	Terminated – Institution Denied (Rehearing Denied)
IPR 2016- 00916	Patent No. 8,900,577	Swiss Pharma Int'l AG	Biogen	Petition: 4/18/16 POPR: 7/20/16 Inst. Dec.: 10/17/16 Reh'g Dec.: 2/3/17	Terminated – Institution Denied (Rehearing Denied)

Enbrel® (Etanercept)

IPR Case No.	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2017- 01916	Patent No. 8,163,522	Coherus	Hoffman- LaRoche	Petition: 8/4/17 POPR: 12/13/17 Inst. Dec.: 3/9/18 Reh'g Dec.: 7/13/18	Terminated – Institution Denied (Rehearing Denied)
IPR 2017- 02066	Patent No. 8,063,182	Coherus	Hoffman- LaRoche	Petition: 9/7/17 POPR: 12/15/17 Inst. Dec.: 3/9/18 Reh'g Dec.: 7/13/18	Terminated – Institution Denied (Rehearing Denied)



IPR 2015- 01792	Patent No. 8,163,522	Coalition for Affordable Drugs	Hoffman- LaRoche	Petition: 8/22/15 POPR: 12/14/15 Inst. Dec.: 3/11/16	Terminated – Institution Denied
-----------------------	--	---	---------------------	--	---

Orencia® (Abatacept)

IPR	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2015- 01537	Patent No. 8,476,239	Momenta	Bristol- Myers Squibb	Petition: 7/2/15 Institution: 1/15/16 Hearing: 9/23/16 Decision: 12/22/16 Notice of Appeal: 2/22/17	Final Written Decision (Notice of Appeal filed)

Epogen® / Procrit® (Epoetin Alfa)

IPR	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2013- 00365	Patent No. 6,747,002	Hospira	Janssen Pharm.	Petition: 6/19/13 Term. Dec.: 10/24/13	Terminated – Adverse Judgment After Statutory Disclaimer

Dupixent® (Dupilumab)

IPR	Patent	Petitioner	Patent Owner	Schedule	Status
IPR 2017- 01884	Patent No. 8,679,487	Sanofi- Aventis	Immunex	Petition: 7/31/17 Institution: 2/15/18 Hearing: 11/14/18 Decision: 2/15/19 (est.)	Trial Instituted
IPR 2017- 01879	Patent No. 8,679,487	Sanofi- Aventis	Immunex	Petition: 7/28/17 Institution: 2/15/18 Hearing: 11/14/18 Decision: 2/15/19 (est.)	Trial Instituted
IPR 2017- 01129	Patent No. 8,679,487	Sanofi- Aventis	Immunex	Petition: 3/23/17 POPR: 7/6/17 Inst. Dec.: 10/4/17	Terminated – Institution Denied